On August 13, 2025, CytomX Therapeutics reported on the Phase 1 study of CX-2051, noting that approximately 20 patients were enrolled at doses of 7.2 mg/kg, 8.6 mg/kg, and 10 mg/kg. One serious treatment-related kidney injury was reported, and the study will continue with a data update expected in Q1 2026.